Af­ter mega-round in­vest­ment, ADC Ther­a­peu­tics cans PhI tri­al in HER2

Af­ter rais­ing a $200 mil­lion mega-round just months ago, Swiss drug­mak­er ADC Ther­a­peu­tics is ax­ing one of its pro­grams due to tox­i­c­i­ty is­sues.

The cut drug pro­gram, called AD­CT-502, is one of the com­pa­ny’s sev­er­al an­ti­body-drug con­ju­gate (ADC) can­di­dates in de­vel­op­ment for sol­id and blood can­cers. The 502 drug was be­ing test­ed in a Phase I tri­al with pa­tients who have HER2-pos­i­tive can­cers. But as the com­pa­ny’s CMO Jay Fein­gold ex­plains it, the HER-2 tar­get­ed ADC wasn’t work­ing well enough in low dos­es, which is a prob­lem con­sid­er­ing the side ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.